BiotechTube
Home/Cantoni Therapeutics/Annegret van der Aa, PhD
AV

Annegret van der Aa, PhD

CEO and Executive Director

Cantoni Therapeutics

Therapeutic Areas

Cardiometabolic DiseaseMetabolic SyndromeType 2 DiabetesObesity

Cantoni Therapeutics Pipeline

DrugIndicationPhase
NNMT Inhibitor ProgramMetabolic Syndrome / Type 2 Diabetes / ObesityPre-clinical